Psyence Biomedical Ratifies Put Option Deal With PsyLabs to Secure Psychedelic Supply

Psyence Biomedical ( (PBM) ) has shared an update.

On February 13, 2026, Psyence Biomedical announced that its board ratified a put option agreement with PsyLabs, allowing PsyLabs to require Psyence to make a future equity investment via a share-for-share exchange at fair market value. The deal sits within a broader strategic relationship, giving Psyence access to PsyLabs’ investigational and commercial-scale manufacturing of pharmaceutical-grade psychedelic compounds.

The structure provides Psyence with a path to potentially acquire a significant stake in PsyLabs while securing predictable, high-quality psychedelic supply for future clinical and commercial programs. By using a put option rather than an immediate cash investment, Psyence preserves near-term financial flexibility and cash for clinical and regulatory execution, although related-party ties prompted a special committee of independent directors to review and ratify the transaction using an external valuation.

More about Psyence Biomedical

Psyence Biomedical Ltd., listed on Nasdaq under the symbol PBM, is a biopharmaceutical company developing nature-derived, non-synthetic psilocybin and ibogaine-based psychedelic medicines. It focuses on evidence-based, FDA-approved treatments targeting unmet mental health needs through a vertically integrated, multi-asset therapeutic platform.

PsyLabs, its strategic partner, is a psychedelic active pharmaceutical ingredient developer licensed to cultivate, extract, and export psilocybin and other compounds to legal medical and research markets. PsyLabs operates an ISO 22000-certified facility, supplying purified psychedelic extracts globally and expanding its pipeline to next-generation psychedelics.

Average Trading Volume: 350,520

Technical Sentiment Signal: Sell

Current Market Cap: $3.03M

Learn more about PBM stock on TipRanks’ Stock Analysis page.